Evernow for Perimenopause and Menopause: An Independent Clinical Review of What the Platform Misses

What Evernow Actually Offers (and What It Claims)

Evernow positions itself as a menopause-specialist telehealth service where women complete an online intake, receive an asynchronous clinician review, and can be prescribed hormone therapy within days. The appeal is real. Fewer than 22% of OB-GYN residency programs include dedicated menopause training, meaning most women cannot easily find an in-person menopause specialist. Evernow addresses that access gap with speed and convenience.

The platform prescribes:

• Systemic estrogen (oral and transdermal)
• Oral micronized progesterone (Prometrium) and progestins
• Compounded and FDA-approved topical testosterone (off-label for women)
• Vaginal estrogen for genitourinary syndrome of menopause (GSM)
• Non-hormonal options including SSRIs, SNRIs, and gabapentin

The question is not whether Evernow is "legit" in the sense of being a licensed medical service. It is. The question is whether the model is complete enough for the clinical complexity menopause actually involves.

The Asynchronous Intake Problem

Most Evernow interactions are asynchronous: you complete a questionnaire, a clinician reviews it, and a prescription follows. This model works reasonably well for straightforward postmenopausal women with classic vasomotor symptoms and no significant medical history. It works less well for:

• Women in early perimenopause with irregular cycles and fluctuating hormone levels, where symptom attribution is genuinely difficult
• Women with a personal or family history of estrogen-receptor-positive breast cancer, who need individualized risk counseling, not a checkbox
• Women with cardiovascular disease, prior thromboembolic events, or active liver disease, for whom ACOG and The Menopause Society have published specific contraindication guidance

Asynchronous review cannot replace a conversation that adapts in real time to what you say next.

Prescribing Scope: Narrower Than It Appears

Evernow's formulary, while adequate for many women, excludes some evidence-based options. Fezolinetant (Veozah), the first non-hormonal neurokinin B antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms, is not consistently listed as a Evernow option. For women who cannot use hormones, this is a meaningful gap.

Perimenopause Specifically: Where the Model Strains Most

Perimenopause is not just "early menopause." It is a hormonally chaotic transition that can last 4 to 10 years and is defined by erratic estradiol fluctuations, not just declining levels. Hot flashes, sleep disruption, mood changes, and cycle irregularity can all appear while estradiol levels are still measurably normal or even transiently elevated.

The Hormone-Level Interpretation Gap

FSH and estradiol drawn on a random day in a perimenopausal woman with irregular cycles are notoriously difficult to interpret. The Menopause Society explicitly states that menopause is a clinical diagnosis in women over 45, not a laboratory one. Yet many women arriving at Evernow have been told by their primary care provider that their labs are "normal," they Google their symptoms, and they expect the telehealth intake to resolve the diagnostic ambiguity. An asynchronous form cannot do that work.

Cycle-Dependent Prescribing Decisions

If you are perimenopausal and still having periods, the choice of progestogen regimen matters differently than in a postmenopausal woman. A woman with an intact uterus who is still cycling needs progestogen to protect the endometrium, but the timing, type, and dose interact with her existing luteal progesterone. Oral micronized progesterone at 200 mg for 12 days per cycle is one evidence-supported approach for perimenopausal women, but determining whether you still have a functional luteal phase requires clinical judgment the asynchronous model rarely provides.

Mental Health Symptoms During Perimenopause

Depression risk roughly doubles during the menopausal transition, particularly in women with a prior depressive episode. Evernow can prescribe SSRIs, which also carry a secondary benefit for vasomotor symptoms. The gap is that prescribing an SSRI through a symptom checklist, without a validated depression screen (PHQ-9) reviewed by a clinician in dialogue with the patient, is not equivalent to a proper mental health assessment. The SSRI may be the right drug, but the clinical reasoning may be insufficient.

The Lab Monitoring Problem

Evernow asks patients to obtain baseline labs (estradiol, FSH, thyroid panel, and sometimes a comprehensive metabolic panel) before starting treatment. Coordination of those results, and follow-up monitoring once therapy begins, is largely patient-driven.

Why This Matters for Women on HRT

Transdermal estradiol bypasses first-pass hepatic metabolism and is generally preferred over oral estradiol for women with cardiovascular risk factors, hypertriglyceridemia, or a history of migraine with aura. Knowing which route is appropriate requires knowing the patient's baseline lipid panel, blood pressure, and migraine history with enough clinical depth to make a defensible recommendation. A form-based intake captures these variables incompletely.

Testosterone Prescribing Without Clear Monitoring

Off-label testosterone for women with hypoactive sexual desire disorder (HSDD) is supported by a 2019 Global Consensus Position Statement from an international panel including ISSWSH and NAMS. That statement specifies that serum total testosterone should be measured before and during treatment to avoid supraphysiologic levels. Supraphysiologic testosterone in women carries risks including acne, hirsutism, clitoral enlargement, and potential lipid effects. Whether Evernow's monitoring pathway reliably fulfills this recommendation is not clearly documented in its public-facing materials.

What Evernow Does Not Address

In-Person Physical Examination

Telehealth cannot perform a bimanual pelvic exam, speculum exam, or breast exam. For a perimenopausal woman with new heavy bleeding, a virtual platform should not be the primary clinician. ACOG recommends endometrial biopsy or transvaginal ultrasound for postmenopausal bleeding and for certain patterns of perimenopausal abnormal uterine bleeding. Evernow's care pathway does not integrate diagnostic imaging or biopsy referral into a coordinated system.

Bone Health

Menopause accelerates bone loss by 1-3% per year in the early postmenopausal years, and the USPSTF recommends bone density screening (DEXA) for women 65 and older, and earlier for younger women with risk factors. Evernow does not appear to build DEXA screening reminders or bone-health risk stratification into its care pathway. Hormone therapy does protect bone, but a woman who has been postmenopausal for several years before starting HRT may have already experienced significant trabecular loss that needs its own evaluation.

Genitourinary Syndrome of Menopause (GSM)

Evernow can prescribe vaginal estrogen, which is appropriate. The gap is that GSM often involves pelvic floor dysfunction, dyspareunia, and bladder symptoms that benefit from pelvic floor physical therapy. A prescription alone, without referral coordination, addresses one piece of a multi-component condition. The Menopause Society's 2023 position statement on GSM lists combined pharmacological and pelvic floor rehabilitation approaches as the evidence-based standard.

Female Pattern Hair Loss and Hormonal Acne

These are visible, distressing manifestations of hormonal change in perimenopause that many women bring to their menopause clinician. They involve androgen sensitivity at the follicle level and may require dermatology collaboration or specific anti-androgen treatment (spironolactone). Evernow's scope does not clearly extend to this clinical territory.

Pregnancy, Lactation, and Contraception: A Required Clinical Section

Systemic hormone therapy, as prescribed by Evernow, is contraindicated in pregnancy. This is not a theoretical concern. Perimenopausal women in their 40s can still ovulate irregularly and conceive. The spontaneous pregnancy rate in women aged 40-44 is approximately 5% per year without contraception, and many women who experience irregular cycles assume they are no longer fertile when they may still be.

Key Points for Perimenopausal Women

• Systemic estrogen and progestogen are not contraceptives. A perimenopausal woman who still has any possibility of ovulation needs reliable contraception if she does not want to conceive.
• ACOG recommends that perimenopausal women continue contraception until 12 months of amenorrhea if under 50, or 6 months if over 50, though guidelines vary.
• Combined hormonal contraceptives (pill, patch, ring) may also manage perimenopausal symptoms and provide contraception simultaneously. These are not part of Evernow's formulary in the way they are in broader reproductive health platforms.

Lactation

Evernow does not serve postpartum or lactating women as a target population. Systemic estrogen suppresses prolactin and can reduce milk supply in lactating women. If a perimenopausal woman is still nursing (rare but possible in early perimenopause), systemic HRT is generally avoided. Vaginal estrogen in very low doses is considered low-risk during lactation but data are limited, and LactMed should be consulted for individual agent review.

Non-Hormonal Options and Pregnancy

Gabapentin and SSRIs/SNRIs prescribed for vasomotor symptoms carry their own pregnancy considerations. Paroxetine (Brisdelle), the only FDA-approved non-hormonal treatment for hot flashes before fezolinetant, carries an FDA warning regarding neonatal adaptation syndrome and potential cardiovascular malformations in first-trimester exposure. Any perimenopausal woman of reproductive potential receiving these medications should be counseled about reliable contraception.

Who Evernow Works Well For (and Who Should Look Elsewhere)

The following framework is based on our clinical team's independent analysis of the Evernow model against published menopause care standards from The Menopause Society and ACOG. No external sponsor influenced this assessment.

Women for Whom Evernow Is a Reasonable Starting Point

• Postmenopausal women (12+ months of amenorrhea) aged 50-60 with classic vasomotor symptoms, no significant cardiovascular history, no personal breast cancer history, and no abnormal uterine bleeding
• Women who have already been evaluated in person and want ongoing prescription management with less friction than repeat specialist visits
• Women in areas with no menopause-trained clinician within reasonable geographic reach
• Women who have read the 2022 Menopause Society hormone therapy position statement and are informed enough to advocate for themselves during the intake process

Women Who Need More Than Evernow Can Provide

• Perimenopausal women with irregular cycles, mood disorders, or suspected thyroid dysfunction requiring differential diagnosis
• Women with a personal or first-degree family history of hormone-receptor-positive breast cancer
• Women with undiagnosed or abnormal uterine bleeding
• Women with cardiovascular disease, prior deep vein thrombosis or pulmonary embolism, active liver disease, or uncontrolled hypertension
• Women who want or need DEXA screening, pelvic floor therapy referral, or oncology co-management coordinated through their menopause care
• Women trying to conceive or currently pregnant (HRT is contraindicated; the platform is not designed for this population)

Evernow vs. Alternatives: A Honest Comparison

Several menopause telehealth platforms have emerged alongside Evernow. Midi Health, Alloy, and Gennev each have different models.

Midi Health uses synchronous video visits with menopause-trained clinicians and accepts some insurance, which changes the access equation for women with coverage. The Menopause Society's "Menopause Practice: A Clinician's Guide" describes synchronous assessment as the standard for women with complex histories. For straightforward cases, the distinction matters less.

Alloy operates a model similar to Evernow in its asynchronous structure. Gennev offers a community component alongside clinical care.

None of these platforms replaces a comprehensive menopause specialist visit, and all of them share the structural limitation that telehealth cannot perform a physical exam. The differentiation is in how much clinical depth the intake process achieves before a prescription is issued.

Cost: What You Actually Pay

Evernow charges approximately $44 per month for platform membership. Medication costs are separate and vary by drug and pharmacy. Compounded testosterone, for example, is not covered by insurance anywhere and typically costs $50-100 per month out of pocket.

A woman managing hot flashes, sleep disruption, GSM, and low libido through Evernow could be paying:

• $44/month (membership)
• $30-60/month (transdermal estradiol patch, Climara or generic)
• $20-40/month (oral micronized progesterone 100 mg)
• $50-100/month (compounded testosterone cream)
• $20-40/month (vaginal estrogen, Vagifem or generic)

That totals $164-284/month before any lab costs. The average annual out-of-pocket cost for menopause care in the United States is estimated at over $2,000 per year for women without adequate specialist coverage, so Evernow may still represent a savings. But women should budget realistically, not just for the membership fee.

The Evidence Gap in Women's Menopausal Care: A Structural Problem Evernow Did Not Create

Women have been under-represented in clinical trials across medical specialties for decades. The Women's Health Initiative (WHI), published in JAMA in 2002, is still the most-cited trial for HRT safety, despite using oral conjugated equine estrogen plus medroxyprogesterone acetate at doses and in populations that do not reflect modern prescribing practice. The ongoing re-analysis of WHI data by researchers including JoAnn Manson has clarified that the risk-benefit calculation is substantially more favorable for women who initiate HRT before age 60 or within 10 years of menopause. A 2023 meta-analysis in The Lancet confirmed that initiating HRT during the "timing window" significantly reduces cardiovascular risk relative to later initiation.

Evernow did not create this evidence gap. But the gap means that any telehealth platform prescribing HRT at scale is doing so on a foundation of evidence that is still evolving. A responsible platform communicates that clearly to patients. Whether Evernow does so consistently is worth asking in your intake conversation.

Questions to Ask Before You Enroll

Before submitting your intake form to any menopause telehealth platform, get clear answers to these:

1. Will I speak to a clinician synchronously before my first prescription is issued?
2. How are my follow-up labs reviewed, and who contacts me if a result is outside range?
3. What happens if I report new abnormal uterine bleeding after starting HRT?
4. Does the platform prescribe fezolinetant if I cannot use hormones?
5. What is the referral pathway if I need a pelvic exam, DEXA, or mammography?
6. If I am perimenopausal and still having periods, does the clinician account for my cycle when choosing my progestogen regimen?

A platform that cannot answer these questions specifically, in writing, is one where the clinical model has limits you should understand before you pay.